Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.

作者: William K. Oh , Daniel J. George , Philip W. Kantoff

DOI: 10.1002/CNCR.10269

关键词:

摘要: BACKGROUND PC-SPES is an herbal supplement whose mechanisms of action are poorly understood, but may be estrogenic. The objective the current report to describe effects discontinuing PC-SPES treatment in four patients with androgen-independent prostate carcinoma. METHODS Patient charts were retrospectively reviewed. A MEDLINE search was performed investigate whether these had been previously reported. RESULTS Four men metastatic carcinoma progressed despite androgen ablation and subsequent described. All developed a rapid increase serum specific antigen (PSA) within one month stopping PC-SPES, ranging from 345% 880%. Two increased their PSA levels 1300% 1400% after 7 weeks. Compared rate rise prior during therapy, this much higher than expected. Clinical symptoms remained relatively stable serologic changes. CONCLUSIONS Discontinuing therapy can associated PSA. To authors' knowledge, effect has not reported previously. This should considered design clinical trials as well standard management patients. Cancer 2002;94:686–9. © 2002 American Society. DOI 10.1002/cncr.10269

参考文章(9)
E J Small, N J Vogelzang, Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. Journal of Clinical Oncology. ,vol. 15, pp. 382- 388 ,(1997) , 10.1200/JCO.1997.15.1.382
Mary Ann Richardson, Tina Sanders, J. Lynn Palmer, Anthony Greisinger, S. Eva Singletary, Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology Journal of Clinical Oncology. ,vol. 18, pp. 2505- 2514 ,(2000) , 10.1200/JCO.2000.18.13.2505
A Manni, M Bartholomew, R Caplan, A Boucher, R Santen, A Lipton, H Harvey, M Simmonds, D White-Hershey, R Gordon, Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. Journal of Clinical Oncology. ,vol. 6, pp. 1456- 1466 ,(1988) , 10.1200/JCO.1988.6.9.1456
B.L. Pfeifer, J.F. Pirani, S.R. Hamann, K.F. Klippel, PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJUI. ,vol. 85, pp. 481- 485 ,(2000) , 10.1046/J.1464-410X.2000.00476.X
William K Oh, Daniel J George, Kristin Hackmann, Judith Manola, Philip W Kantoff, Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology. ,vol. 57, pp. 122- 126 ,(2001) , 10.1016/S0090-4295(00)00986-9
Robert S. DiPaola, Huayan Zhang, George H. Lambert, Robert Meeker, Edward Licitra, Mohamed M. Rafi, Bao Ting Zhu, Heidi Spaulding, Susan Goodin, Michel B. Toledano, William N. Hait, Michael A. Gallo, Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate Cancer The New England Journal of Medicine. ,vol. 339, pp. 785- 791 ,(1998) , 10.1056/NEJM199809173391201
Eric J. Small, Mark W. Frohlich, Robert Bok, Katsuto Shinohara, Gary Grossfeld, Zinovi Rozenblat, Wm. Kevin Kelly, Michele Corry, David M. Reese, Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer Journal of Clinical Oncology. ,vol. 18, pp. 3595- 3603 ,(2000) , 10.1200/JCO.2000.18.21.3595
Howard I Scher, WM Kevin Kelly, Zuo-Feng Zhang, Peter Ouyang, Min Sun, Morton Schwartz, Cliff Ding, Weiping Wang, Ivan D Horak, Alton B Kremer, Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer Journal of the National Cancer Institute. ,vol. 91, pp. 244- 251 ,(1999) , 10.1093/JNCI/91.3.244
Fernand Labrie, Andre Dupont, Alain Belanger, Roger Lachance, Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone Agonist The Journal of Urology. ,vol. 138, pp. 804- 806 ,(1987) , 10.1016/S0022-5347(17)43380-5